Nature Communications (Feb 2016)
RUNX1 prevents oestrogen-mediated AXIN1 suppression and β-catenin activation in ER-positive breast cancer
- Nyam-Osor Chimge,
- Gillian H. Little,
- Sanjeev K. Baniwal,
- Helty Adisetiyo,
- Ying Xie,
- Tian Zhang,
- Andie O’Laughlin,
- Zhi Y. Liu,
- Peaches Ulrich,
- Anthony Martin,
- Paulette Mhawech-Fauceglia,
- Matthew J. Ellis,
- Debu Tripathy,
- Susan Groshen,
- Chengyu Liang,
- Zhe Li,
- Dustin E. Schones,
- Baruch Frenkel
Affiliations
- Nyam-Osor Chimge
- Department of Medicine, Keck School of Medicine of the University of Southern California
- Gillian H. Little
- Institute for Genetic Medicine, Keck School of Medicine of the University of Southern California
- Sanjeev K. Baniwal
- Institute for Genetic Medicine, Keck School of Medicine of the University of Southern California
- Helty Adisetiyo
- Institute for Genetic Medicine, Keck School of Medicine of the University of Southern California
- Ying Xie
- Division of Genetics, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School
- Tian Zhang
- Department of Molecular Microbiology and Immunology, Keck School of Medicine of the University of Southern California
- Andie O’Laughlin
- Institute for Genetic Medicine, Keck School of Medicine of the University of Southern California
- Zhi Y. Liu
- Institute for Genetic Medicine, Keck School of Medicine of the University of Southern California
- Peaches Ulrich
- Institute for Genetic Medicine, Keck School of Medicine of the University of Southern California
- Anthony Martin
- Institute for Genetic Medicine, Keck School of Medicine of the University of Southern California
- Paulette Mhawech-Fauceglia
- Department of Pathology, Keck School of Medicine of the University of Southern California
- Matthew J. Ellis
- Smith Breast Center, Baylor College of Medicine
- Debu Tripathy
- Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center
- Susan Groshen
- Department of Preventive Medicine, Keck School of Medicine of the University of Southern California
- Chengyu Liang
- Department of Molecular Microbiology and Immunology, Keck School of Medicine of the University of Southern California
- Zhe Li
- Division of Genetics, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School
- Dustin E. Schones
- Department of Diabetes Complications and Metabolism, Beckman Research Institute, City of Hope
- Baruch Frenkel
- Institute for Genetic Medicine, Keck School of Medicine of the University of Southern California
- DOI
- https://doi.org/10.1038/ncomms10751
- Journal volume & issue
-
Vol. 7,
no. 1
pp. 1 – 12
Abstract
The tumour suppressor RUNX1 is often lost or mutated in oestrogen receptor-positive breast cancers. In this study, the authors demonstrate that the loss of RUNX1 unleashes oestrogen-mediated inhibition of AXIN1, a negative regulator of β-catenin, resulting in β-catenin signalling-mediated cancer cell proliferation and mitosis deregulation.
